{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:06:22Z","timestamp":1790723182681,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-025-03426-x","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:57:39Z","timestamp":1770879459000},"page":"1562-1581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Addressing the Challenges in the Identification of HER2-Low and Ultralow Breast Cancer in Asia: A Delphi Consensus"],"prefix":"10.1007","volume":"43","author":[{"given":"Milap","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowen T.","family":"Yolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethy S.","family":"Hernowo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung Nguyen","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Gyungyub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Irianiwati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu Bach","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuelito A.","family":"Madrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pathmanathan","family":"Rajadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pichet","family":"Sampatanukul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shir-Hwa","family":"Ueng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Pasricha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Yongcheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puay Hoon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tikamporn","family":"Jitpasutham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"3426_CR1","first-page":"4","volume":"2","author":"T Ishikawa","year":"2014","unstructured":"Ishikawa T, Ichikawa Y, Shimizu D, et al. The role of HER-2 in breast cancer. J Surg Sci. 2014;2:4\u20139.","journal-title":"J Surg Sci"},{"key":"3426_CR2","unstructured":"HER2 in Breast Cancer: ESMO Biomarker Factsheet. https:\/\/oncologypro.esmo.org\/education-library\/factsheets-on-biomarkers\/her2-in-breast-cancer. Accessed 2024 Nov 28."},{"key":"3426_CR3","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor\u00a02 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322.","journal-title":"J Clin Oncol"},{"key":"3426_CR4","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor\u00a02 testing in breast cancer: ASCO\u2013College of American Pathologists guideline update. J Clin Oncol. 2023;41:3867\u201372.","journal-title":"J Clin Oncol"},{"key":"3426_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00428-023-03656-w","volume":"484","author":"M Ivanova","year":"2024","unstructured":"Ivanova M, Porta FM, D\u2019Ercole M, et al. Standardized pathology report for HER2 testing in compliance with 2023 ASCO\/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch. 2024;484:3\u201314.","journal-title":"Virchows Arch"},{"key":"3426_CR6","doi-asserted-by":"publisher","first-page":"12382","DOI":"10.1038\/s41598-023-39372-3","volume":"13","author":"M Yang","year":"2023","unstructured":"Yang M, Sun J, Liu L, et al. Clinicopathological characteristics of HER2-low breast cancer: a retrospective study. Sci Rep. 2023;13:12382.","journal-title":"Sci Rep"},{"key":"3426_CR7","unstructured":"US Food and Drug Administration. FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer. FDA. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer. Accessed 2024 Nov 29."},{"key":"3426_CR8","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2217\/fon-2024-0015","volume":"20","author":"V Guarneri","year":"2024","unstructured":"Guarneri V, Passos Coelho JL, Duhoux FP, et al. Study design for DESTINY-Breast respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer. Fut Oncol. 2024;20:1237\u201350.","journal-title":"Fut Oncol"},{"key":"3426_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320.","journal-title":"N Engl J Med"},{"key":"3426_CR10","doi-asserted-by":"publisher","unstructured":"Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2407086. Accessed 2024 Nov 29.","DOI":"10.1056\/NEJMoa2407086"},{"key":"3426_CR11","doi-asserted-by":"publisher","unstructured":"Curigliano G, Hu X, Dent RA, et al. Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor\u00a02 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). J Clin Oncol. 2024https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA1000.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000"},{"key":"3426_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13058-023-01739-9","volume":"25","author":"K Nielsen","year":"2023","unstructured":"Nielsen K, Sode M, Jensen M-B, et al. High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients. Breast Cancer Res. 2023;25:139.","journal-title":"Breast Cancer Res"},{"key":"3426_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132325","volume":"16","author":"P Rajadurai","year":"2024","unstructured":"Rajadurai P, Ravindran S, Lee BR, et al. Consensus guidelines on human epidermal growth factor receptor\u00a02 (HER2)-low testing in breast cancer in Malaysia. Cancers. 2024;16:2325.","journal-title":"Cancers"},{"key":"3426_CR14","doi-asserted-by":"publisher","first-page":"1176309","DOI":"10.3389\/fmolb.2023.1176309","volume":"10","author":"E Sajjadi","year":"2023","unstructured":"Sajjadi E, Guerini-Rocco E, De Camilli E, et al. Pathological identification of HER2-low breast cancer: tips, tricks, and troubleshooting for the optimal test. Front Mol Biosci. 2023;10:1176309.","journal-title":"Front Mol Biosci"},{"key":"3426_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/labinvest.2015.138","volume":"96","author":"SE Combs","year":"2016","unstructured":"Combs SE, Han G, Mani N, Beruti S, Nerenberg M, Rimm DL. Loss of antigenicity with tissue age in breast cancer. Lab Investig J Tech Methods Pathol. 2016;96:264\u20139.","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"3426_CR16","doi-asserted-by":"crossref","unstructured":"Rajadurai P, Ravindran S, Lee BR, et al. Consensus guidelines on human epidermal growth factor receptor\u00a02 (HER2)-low testing in breast cancer in Malaysia. Cancers (Basel). 2024;16(13):2325.","DOI":"10.3390\/cancers16132325"},{"key":"3426_CR17","doi-asserted-by":"crossref","unstructured":"R\u00fcschoff J, Penner A, Ellis IO, et al. Global study on the accuracy of human epidermal growth factor receptor\u00a02-low diagnosis in breast cancer. Arch Pathol Lab Med. 2025;149(5):431\u2013438.","DOI":"10.5858\/arpa.2024-0052-OA"},{"key":"3426_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100535","volume":"37","author":"G Farshid","year":"2024","unstructured":"Farshid G, Armes J, Dessauvagie B, et al. Development and validation of a HER2-low focused immunohistochemical scoring system with high-interobserver concordance: the Australian HER2-low breast cancer concordance study. Mod Pathol. 2024;37:100535.","journal-title":"Mod Pathol"},{"issue":"10","key":"3426_CR19","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/modpathol.2008.83","volume":"21","author":"AM Gown","year":"2008","unstructured":"Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008;21(10):1271\u20137.","journal-title":"Mod Pathol"},{"key":"3426_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10549-023-07079-8","volume":"202","author":"Z Chen","year":"2023","unstructured":"Chen Z, Jia H, Zhang H, et al. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat. 2023;202:313\u201323.","journal-title":"Breast Cancer Res Treat"},{"key":"3426_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaoncol.2022.7476","volume":"9","author":"DS Peiffer","year":"2023","unstructured":"Peiffer DS, Zhao F, Chen N, et al. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol. 2023;9:500\u201310.","journal-title":"JAMA Oncol"},{"key":"3426_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12916-022-02284-6","volume":"20","author":"RSYC Tan","year":"2022","unstructured":"Tan RSYC, Ong WS, Lee K-H, et al. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Med. 2022;20:105.","journal-title":"BMC Med"},{"key":"3426_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Viale G, Press MF, et al. Esmo expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34:645\u201359.","journal-title":"Ann Oncol"},{"key":"3426_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/fampra\/cmp051","volume":"26","author":"M Thompson","year":"2009","unstructured":"Thompson M. Considering the implication of variations within Delphi research. Fam Pract. 2009;26:420\u20134.","journal-title":"Fam Pract"},{"key":"3426_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020476","volume":"6","author":"R Boulkedid","year":"2011","unstructured":"Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One. 2011;6:e20476.","journal-title":"PLoS One"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03426-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03426-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03426-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:14:16Z","timestamp":1775726056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03426-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3426"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03426-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Milap Shah, Bethy S Hernowo, Trung Nguyen Cong, Gong Gyungyub, Irianiwati, Lu Bach Kim, Manuelito A. Madrid, Pathmanathan Rajadurai, Sunil Pasricha, Benjamin Yongcheng Tan and Tikamporn Jitpasutham declare no conflicts in this work. Rowen T. Yolo, Pichet Sampatanukul have received honorarium and travel support from AstraZeneca. Shir-Hwa Ueng has received honorarium and travel support from AstraZeneca and Discovery Life Science and serves as Council member of the Taiwan Society of Pathology, Breast Cancer Committee. Puay Hoon Tan has received honoraria and travel support from AstraZeneca and Singapore Pathology and also holds shares in Tamarind Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As this was a non-interventional, physician-based Delphi consensus, formal IRB approval was not required. The study did not involve vulnerable populations, identifiable personal or clinical data, or human tissue samples; therefore, the Declaration of Helsinki also does not apply. Prior to the consensus process, participants were fully informed of the study objectives. Participation was voluntary, responses reflected independent opinions and were anonymized, and no sensitive or patient-related information was collected. All data were handled confidentially, and informed consent was obtained from all participating pathologists before initiating the virtual surveys. Participants were aware that study results would be published. All data informing the consensus guideline were sourced from publicly available information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}